A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2014
At a glance
- Drugs MVA 85A (Primary) ; Tuberculosis vaccine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 07 Oct 2014 Accrual to date is 134% according to United Kingdom Clinical Research Network
- 16 Sep 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 10 Apr 2014 Accrual to date is 102% according to United Kingdom Clinical Research Network.